Sarepta Therapeutics, Inc. SRPT
16.42 USD -0.82 (-4.76%)
At closeNov 10, 2026, 4:17 PM EST
16.40 -0.02 -0.12%
After hours · Nov 10, 4:17 PM ET
16.14 Day range 17.59
14.68 52-week range 24.68
- YTD
- -23.70%
- 1 year
- -4.92%
News
seekingalpha.com Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript Sarepta Therapeutics, Inc. ( SRPT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO…
benzinga.com RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Raises Price Target to $18 RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and raises the price target from $17 to $18.
marketbeat.com Sarepta Therapeutics Q3 Earnings Call Highlights Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued…
benzinga.com Sarepta Therapeutics Q3 2026 Earnings Call Transcript Sarepta Therapeutics (NASDAQ:SRPT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Sarepta Therapeutics Q3 Adj. EPS $0.13 Beats $0.06 Estimate, Sales $381.400M Beat $352.961M Estimate Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.06 by 116.67 percent. This is a 200 percent increase over losses of…
benzinga.com RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17 RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.
benzinga.com Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’ Cramer called Sarepta controversial, praised Avery Dennison and Ciena, favored ING and Santander, and declined to endorse FirstCash.
benzinga.com HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
benzinga.com JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20 JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
benzinga.com Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2…
benzinga.com REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta
benzinga.com Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
benzinga.com A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
benzinga.com Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
benzinga.com Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.26 by 146.15 percent. This is a 68.32 percent decrease over earnings…
benzinga.com Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective…- benzinga.com Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20 Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
benzinga.com Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.
benzinga.com Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a decision expected by February 2027.
benzinga.com Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027 – Accepted for review with target action date of February 28, 2027Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S.…
benzinga.com Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps leading the tape, as investors held their fire ahead of Kevin Warsh‘s first interest-rate decision as…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
benzinga.com 9 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday? U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, heavily weighted toward tech stocks, officially entered correction territory.- benzinga.com Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13 Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.
benzinga.com Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 And AMD: Why These 5 Stocks Are On Investors' Radars Today U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49, the S&P 500 gaining 0.5% to 6,591.90.
benzinga.com Crude Oil Moves Lower; Cintas Raises FY2026 Forecast The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp posted strong earnings and raised its forecast, while Sarepta Therapeutics and Braze Inc saw…
benzinga.com Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics surges 29%. Oil down 2.1%, gold up 3.2%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Stocks Rise, Oil Falls On Iran Ceasefire Hopes, ARM Surges 15% : What's Moving Markets Wednesday? U.S. stocks advanced Wednesday as oil prices fell on Iran diplomacy reports. Arm jumped 15%, while Treasury yields declined.
benzinga.com Why Is Sarepta Therapeutics Stock Exploding Today? Sarepta stock jumps after siRNA data show protein reduction, while analysts remain split on outlook and valuation.- benzinga.com Sarepta Reports Early siRNA Trial Results With Strong Muscle Targeting And Favorable Safety Profile In early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1Company to host investor call on March…
benzinga.com Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs Sarepta stock slips after FDA update and mixed trial results, as investors weigh approval hopes against weak data signals.- benzinga.com Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $37 Price Target Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $37 price target.
- benzinga.com Sarepta Therapeutics Provides Update On Ongoing Regulatory Interactions With FDA Regarding AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy – Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approvalSarepta Therapeutics, Inc.…
- benzinga.com Sarepta Begins Enrolling Non-Ambulatory Duchenne Patients In ENDEAVOR Cohort Testing Sirolimus Safety Protocol With ELEVIDYS - Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study- The enhanced immunosuppressive regimen is designed to mitigate the risk…
benzinga.com Mizuho Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $31 Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $26 to $31.- benzinga.com Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $9 Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $8 to $9.
benzinga.com What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
benzinga.com Why Is uniQure Stock Skyrocketing Monday? uniQure (QURE) stock surges following news of CBER director Vinay Prasad's exit. See why the market is reacting so strongly.- benzinga.com HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
benzinga.com Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - benzinga.com Wells Fargo Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $38 Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target from $45 to $38.
- benzinga.com Sarepta Therapeutics To Present Data Muscular Dystrophy Association Clinical & Scientific Conference Across Its Rare Neuromuscular Portfolio Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking…
benzinga.com Sarepta CEO To Jump Ship After 'Tumultuous' Year Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.- benzinga.com Sarepta Therapeutics Q4 Adj. EPS $(3.58) Misses $(1.31) Estimate, Sales $442.934M Beat $391.924M Estimate Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(3.58) per share which missed the analyst consensus estimate of $(1.31) by 172.45 percent. This is a 288.42 percent decrease over…
- benzinga.com Earnings Scheduled For February 25, 2026